Clinical Trial Update: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Belrestotug plus dostarlimab vs placebo plus pembrolizumab in untreated PD-L1-high non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Belrestotug (belrestotug)
• Dostarlimab (dostarlimab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lung Cancer, Non-Small Cell | Phase 3 | Status: ACTIVE_NOT_RECRUITING